ALERT: Lawsuit filed for Investors who lost money with shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT)

An investor, who purchased shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT), filed a lawsuit over alleged violations of Federal Securities Laws by PROCEPT BioRobotics Corporation in connection with certain allegedly false and misleading statements.

Investors who purchased shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) have certain options and for certain investors are short and strict deadlines running. Deadline: September 22, 2026. NASDAQ: PRCT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

San Jose, CA based PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally.

On August 6, 2025, PROCEPT BioRobotics Corporation announced earnings for its second fiscal quarter of 2025, revealing that Procept had only sold approximately 12,750 handpieces in the United States during the quarter. During Procept's earnings call, defendant Kevin Waters reported that Procept expected to ship approximately 13,350 units in the following quarter, significantly below consensus estimates of more than 13,840 units. Procept's quarterly handpiece sales guidance also implied that Procept would need to grow handpiece sales by approximately 25% year-over-year in the fourth quarter in order to meet Procept's annual unit sales guidance. In addition, defendant Reza Zadno revealed that Procept was eliminating the role of Chief Commercial Officer in order to "strengthen" Procept's "commercial execution."

Then, on November 4, 2025, PROCEPT BioRobotics Corporation announced earnings results for its third fiscal quarter of 2025, revealing that Procept had only sold 13,225 handpieces during the quarter, which missed Procept's sales guidance issued during the prior quarter. During the corresponding conference call, defendant Kevin Waters further revealed that Procept was reducing its annual handpiece sales guidance by 1,000 units, down from 53,000 units to 52,000 units to allow for the "optimization of field inventory." Defendant Larry L. Wood further admitted that Procept had not "been managing customer inventory by establishing par levels" and that some customers were "probably carrying too much inventory."

Finally, on February 25, 2026, PROCEPT BioRobotics Corporation announced earnings results for its fourth fiscal quarter and year ending December 31, 2025. PROCEPT BioRobotics Corporation (NASDAQ: PRCT) reported that its annual Total Revenue rose from $224.50 million in 2024 to $308.05 million in 2025, and that its Net Loss increased from $91.41 million in 2024 to $95.57 million in 2025. PROCEPT BioRobotics Corporation revealed that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential which had consistently grown over time, ultimately resulting in cumulative excess field inventory of more than 10,000 units. Procept further revealed that quarterly handpiece unit sales in the United States had declined significantly from 13,225 units in the third quarter to 9,400 units, representing a sequential decline of nearly 30%.

Shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) declined from $103.81 per share on November 11, 2024 to $16.67 per share on July 24, 2026.

The plaintiff claims that between February 28, 2024 and February 25, 2026, the defendants made materially false and/or misleading statements because they failed to disclose the following adverse facts pertaining to Procept's business, operations, and financial condition, which were known to defendants or recklessly disregarded by them as follows that, between February 28, 2024 and February 25, 2026, Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand, that Procept's undisclosed discount program had artificially and unsustainably inflated Procept's reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods, that Procept's undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; that Procept's consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept's customer base, amounting to more than 10,000 excess units by the end of between February 28, 2024 and February 25, 2026, that, as a result of the above, defendants' representations between February 28, 2024 and February 25, 2026regarding Procept's handpiece unit sales and the utilization of Procept's field Systems were materially overstated, that, as a result of the above, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm, and that, as a result of the above, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.

Those who purchased shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.